The Experts below are selected from a list of 1470 Experts worldwide ranked by ideXlab platform
Tadafumi Tamura - One of the best experts on this subject based on the ideXlab platform.
-
Olopatadine hydrochloride suppresses hot flashes induced by topical treatment with tacrolimus ointment in rats.
European journal of pharmacology, 2015Co-Authors: Kyosuke Satake, Tadafumi Tamura, Toru Amano, Junichi Ikeda, Katsuya KobayashiAbstract:Tacrolimus ointment is prescribed for patients with atopic dermatitis, although it is known to cause transient burning sensations and hot flashes in the applied skin. The aim of this study was to evaluate the effects of Olopatadine hydrochloride (Olopatadine), an antiallergic agent with a histamine H1 receptor (H1R) antagonistic activity, on the incidence of hot flashes induced by topical treatment with tacrolimus ointment in rats. Consequently, the skin temperature was increased by the topical application of tacrolimus ointment in rats, and the rise in skin temperature was inhibited by pretreatment with Olopatadine in a dose-dependent manner. Inhibitory effect of Olopatadine on tacrolimus-induced skin temperature elevation was significantly more potent than that of cetirizine hydrochloride, other antiallergic agent with H1R antagonistic activity, at doses in which both agents exhibit comparable H1R antagonistic activity in rats. These results suggest that H1R antagonistic activity-independent mechanism contribute to the inhibitory effect of Olopatadine on tacrolimus-induced skin temperature elevation. Olopatadine also significantly inhibited increases in vascular permeability and nerve growth factor production in the skin induced by topical tacrolimus treatment. Thus, the onset of hot flashes in rats is quantitatively determined by measuring the skin temperature and Olopatadine attenuates hot flashes induced by topical tacrolimus ointment in rats, suggesting that the combination application with Olopatadine and tacrolimus ointment is useful for improving medication adherence with tacrolimus ointment treatment in patients with atopic dermatitis.
-
Properties of Olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Arzneimittel-Forschung, 2011Co-Authors: Kenji Ohmori, Tadafumi Tamura, Kiyomi Miyake, Kaori Horikoshi, Akira Karasawa, Masahiro Matsubara, Kazuhide Hasegawa, Shigehiro Masaki, Naoko Urayama, Jiro KajitaAbstract:Olopatadine hydrochloride (CAS 140462-76-6, KW-4679, AL-4943A; hereinafter referred to as Olopatadine) is a novel antiallergic drug that is a selective histamine H1 receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. Olopatadine also inhibits the tachykininergic contractions in guinea pig bronchi by prejunctional inhibition of peripheral sensory nerves. Oral administration of Olopatadine at doses of 0.03 mg/kg or higher reduces the symptoms of experimental allergic cutaneous responses and rhinoconjunctivitis in sensitized animals. Preclinical and clinical evaluations have demonstrated that Olopatadine is a safe drug. After oral administration to healthy volunteers, Olopatadine was rapidly and extensively absorbed. Unlike most other antiallergic drugs which are eliminated via hepatic metabolism, Olopatadine is mainly excreted into urine. Olopatadine did not affect cytochrome P450 activities in human liver microsomes and consequently drug-drug metabolic interactions are unlikely. In doublemasked clinical trials, Olopatadine was shown to be effective at alleviating symptoms of allergic diseases. The drug (Allelock®) was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, cutaneous pruritis, psoriasis vulgaris and erythema exsudativum multiforme in December, 2000. An ophthalmic solution of Olopatadine is also useful for the treatment of allergic conjunctivitis: this formulation (Patanol®) was approved in the USA and the European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.
-
properties of Olopatadine hydrochloride a new antiallergic antihistaminic drug
Drug Research, 2011Co-Authors: Kenji Ohmori, Tadafumi Tamura, Kiyomi Miyake, Kaori Horikoshi, Akira Karasawa, Masahiro Matsubara, Kazuhide Hasegawa, Shigehiro Masaki, Naoko Urayama, Jiro KajitaAbstract:Olopatadine hydrochloride (CAS 140462-76-6, KW-4679, AL-4943A; hereinafter referred to as Olopatadine) is a novel antiallergic drug that is a selective histamine H1 receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. Olopatadine also inhibits the tachykininergic contractions in guinea pig bronchi by prejunctional inhibition of peripheral sensory nerves. Oral administration of Olopatadine at doses of 0.03 mg/kg or higher reduces the symptoms of experimental allergic cutaneous responses and rhinoconjunctivitis in sensitized animals. Preclinical and clinical evaluations have demonstrated that Olopatadine is a safe drug. After oral administration to healthy volunteers, Olopatadine was rapidly and extensively absorbed. Unlike most other antiallergic drugs which are eliminated via hepatic metabolism, Olopatadine is mainly excreted into urine. Olopatadine did not affect cytochrome P450 activities in human liver microsomes and consequently drug-drug metabolic interactions are unlikely. In doublemasked clinical trials, Olopatadine was shown to be effective at alleviating symptoms of allergic diseases. The drug (Allelock®) was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, cutaneous pruritis, psoriasis vulgaris and erythema exsudativum multiforme in December, 2000. An ophthalmic solution of Olopatadine is also useful for the treatment of allergic conjunctivitis: this formulation (Patanol®) was approved in the USA and the European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.
-
Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.
Pharmacology, 2007Co-Authors: Tadafumi Tamura, Toru Amano, Masahiro Matsubara, Michihiro ChidaAbstract:Olopatadine hydrochloride (Olopatadine) is an antiallergic agent with histamine H1 receptor antagonistic action. We investigated the possible efficacies of Olopatadine on the chronic inflam
-
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein
Mediators of inflammation, 2006Co-Authors: Kazuya Kishimoto, Tadafumi Tamura, Kenji Ohmori, Satoshi Kaneko, Kazuhide HasegawaAbstract:Olopatadine hydrochloride (Olopatadine) is an antiallergic drug with histamine H1 receptor antagonistic activity. Recently, Olopatadine has been shown to bind to S100A12 which is a member of the S100 family of calcium-binding proteins, and exerts multiple proinflammatory activities including chemotaxis for monocytes and neutrophils. In this study, we examined the possibility that the interaction of Olopatadine with S100A12 inhibits the proinflammatory effects of S100A12. Pretreatment of Olopatadine with S100A12 reduced migration of THP-1, a monocyte cell line, induced by S100A12 alone, but did not affect recombinant human regulated upon activation, normal T cell expressed and secreted (RANTES)-induced migration. Amlexanox, which also binds to S100A12, inhibited the THP-1 migration induced by S100A12. However, ketotifen, another histamine H1 receptor antagonist, had little effect on the activity of S100A12. These results suggest that Olopatadine has a new mechanism of action, that is, suppression of the function of S100A12, in addition to histamine H1 receptor antagonistic activity.
Toru Amano - One of the best experts on this subject based on the ideXlab platform.
-
Olopatadine hydrochloride suppresses hot flashes induced by topical treatment with tacrolimus ointment in rats.
European journal of pharmacology, 2015Co-Authors: Kyosuke Satake, Tadafumi Tamura, Toru Amano, Junichi Ikeda, Katsuya KobayashiAbstract:Tacrolimus ointment is prescribed for patients with atopic dermatitis, although it is known to cause transient burning sensations and hot flashes in the applied skin. The aim of this study was to evaluate the effects of Olopatadine hydrochloride (Olopatadine), an antiallergic agent with a histamine H1 receptor (H1R) antagonistic activity, on the incidence of hot flashes induced by topical treatment with tacrolimus ointment in rats. Consequently, the skin temperature was increased by the topical application of tacrolimus ointment in rats, and the rise in skin temperature was inhibited by pretreatment with Olopatadine in a dose-dependent manner. Inhibitory effect of Olopatadine on tacrolimus-induced skin temperature elevation was significantly more potent than that of cetirizine hydrochloride, other antiallergic agent with H1R antagonistic activity, at doses in which both agents exhibit comparable H1R antagonistic activity in rats. These results suggest that H1R antagonistic activity-independent mechanism contribute to the inhibitory effect of Olopatadine on tacrolimus-induced skin temperature elevation. Olopatadine also significantly inhibited increases in vascular permeability and nerve growth factor production in the skin induced by topical tacrolimus treatment. Thus, the onset of hot flashes in rats is quantitatively determined by measuring the skin temperature and Olopatadine attenuates hot flashes induced by topical tacrolimus ointment in rats, suggesting that the combination application with Olopatadine and tacrolimus ointment is useful for improving medication adherence with tacrolimus ointment treatment in patients with atopic dermatitis.
-
Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.
Pharmacology, 2007Co-Authors: Tadafumi Tamura, Toru Amano, Masahiro Matsubara, Michihiro ChidaAbstract:Olopatadine hydrochloride (Olopatadine) is an antiallergic agent with histamine H1 receptor antagonistic action. We investigated the possible efficacies of Olopatadine on the chronic inflam
-
the effects of Olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice
European Journal of Pharmacology, 2005Co-Authors: Tadafumi Tamura, Toru Amano, Kenji Ohmori, Haruhiko ManabeAbstract:Abstract It is suggested that atopic dermatitis is a skin disease associated with itching as subjective symptoms, and histamine H1 receptor antagonists are used in order to prevent the itching, and the deterioration for scratch by itching. Histamine H1 receptor selective anti-histamine Olopatadine hydrochloride (Olopatadine; Allelock®) shows consistent efficacy and safety in the treatment of allergic disorders. We investigated the possible efficacy of Olopatadine on the number of scratching induced by repeated application of oxazolone in BALB/c mice. The repeated treatment of Olopatadine significantly inhibited the ear swelling and the increased number of scratching. It significantly inhibited the increased production of interleukin (IL)-4, IL-1β and granulocyte–macrophage colony-stimulating factor (GM-CSF) in the lesioned ear. Moreover, it significantly inhibited the increased production of nerve growth factor (NGF) and substance P. On the other hand, loratadine, bepotastine and chlorpheniramine did not inhibit the ear swelling and the increased number of scratching. These results indicate that Olopatadine inhibited not only the increased production of cytokines but also NGF and substance P unlike other histamine H1 receptor antagonists. It was suggested that Olopatadine suppressed the increased number of scratching by the anti-inflammatory effects. Therefore, Olopatadine appears to exert additional biological effects besides its blockade of a histamine H1 receptor.
-
The effects of Olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.
European journal of pharmacology, 2005Co-Authors: Tadafumi Tamura, Toru Amano, Kenji Ohmori, Haruhiko ManabeAbstract:It is suggested that atopic dermatitis is a skin disease associated with itching as subjective symptoms, and histamine H(1) receptor antagonists are used in order to prevent the itching, and the deterioration for scratch by itching. Histamine H(1) receptor selective anti-histamine Olopatadine hydrochloride (Olopatadine; Allelock shows consistent efficacy and safety in the treatment of allergic disorders. We investigated the possible efficacy of Olopatadine on the number of scratching induced by repeated application of oxazolone in BALB/c mice. The repeated treatment of Olopatadine significantly inhibited the ear swelling and the increased number of scratching. It significantly inhibited the increased production of interleukin (IL)-4, IL-1beta and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the lesioned ear. Moreover, it significantly inhibited the increased production of nerve growth factor (NGF) and substance P. On the other hand, loratadine, bepotastine and chlorpheniramine did not inhibit the ear swelling and the increased number of scratching. These results indicate that Olopatadine inhibited not only the increased production of cytokines but also NGF and substance P unlike other histamine H(1) receptor antagonists. It was suggested that Olopatadine suppressed the increased number of scratching by the anti-inflammatory effects. Therefore, Olopatadine appears to exert additional biological effects besides its blockade of a histamine H(1) receptor.
G. Michael Wall - One of the best experts on this subject based on the ideXlab platform.
-
Olopatadine nasal spray for the treatment of allergic rhinitis.
Expert Review of Clinical Immunology, 2010Co-Authors: Peter S Roland, Bradley F. Marple, G. Michael WallAbstract:Olopatadine hydrochloride nasal spray (Patanase® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of Olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, Olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.
-
The effects of the nasal antihistamines Olopatadine and azelastine in nasal allergen provocation
Annals of Allergy Asthma & Immunology, 2008Co-Authors: Patrik Pipkorn, Candy Costantini, Alvin M. Sanico, Curt Reynolds, M. Drake, David Proud, G. Michael Wall, Alkis TogiasAbstract:Background Olopatadine, an antihistamine used in allergic conjunctivitis, is under development as a nasal preparation for the treatment of allergic rhinitis. Objectives To evaluate the efficacy of Olopatadine in suppressing symptoms and biomarkers of the immediate reaction induced by nasal allergen provocation and to compare Olopatadine with azelastine in the same model. Methods The study was approved by the Johns Hopkins University institutional review board, and all subjects gave written consent. We studied 20 asymptomatic subjects with seasonal allergic rhinitis. The study had 2 randomized, double-blind, placebo-controlled, crossover phases that evaluated 2 concentrations of Olopatadine, 0.1% and 0.2%. In a third exploratory phase, Olopatadine, 0.1%, was compared with topical azelastine, 0.1%, in a patient-masked design. Efficacy variables were the allergen-induced sneezes, other clinical symptoms, and the levels of histamine, tryptase, albumin, lysozyme, and cysteinyl-leukotrienes (third study only) in nasal lavage fluids. Results Both concentrations of Olopatadine produced significant inhibition of all nasal symptoms, compared with placebo. Olopatadine, 0.1%, inhibited lysozyme levels, but Olopatadine, 0.2%, inhibited histamine, albumin, and lysozyme. The effects of Olopatadine, 0.1%, were comparable to those of azelastine, 0.1%. Conclusions Olopatadine, at 0.1% and 0.2% concentrations, was effective in suppressing allergen-induced nasal symptoms. At 0.2%, Olopatadine provided evidence suggestive of inhibition of mast cell degranulation.
-
An assessment of the onset and duration of action of Olopatadine nasal spray
Otolaryngology-Head and Neck Surgery, 2007Co-Authors: Piyush Patel, Bradley F. Marple, Paul J. Benninger, Harriet Margalias, M. Brubaker, Susan F. Beezley, Susan L. Potts, M. Drake, Peter S Roland, G. Michael WallAbstract:OBJECTIVE: Seasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of Olopatadine nasal spray. METHODS: This was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to Olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period. RESULTS: All concentrations of Olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P < 0.05) than placebo nasal spray at all time-points starting at 90 minutes post-dose and continuing over 12 hours. CONCLUSIONS: Olopatadine nasal spray 0.6% demonstrated a fast onset of action and maintained an effect for at least 12 hours after dosing.
-
An assessment of the onset and duration of action of Olopatadine nasal spray
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007Co-Authors: Piyush Patel, Bradley F. Marple, Paul J. Benninger, Harriet Margalias, Susan F. Beezley, Susan L. Potts, Peter S Roland, Margaret Drake, Michael J. Brubaker, G. Michael WallAbstract:ObjectiveSeasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of Olopatadine nasal spray.METHODSThis was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to Olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period.RESULTSAll concentrations of Olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P
-
Improved quality of life among seasonal allergic rhinitis patients treated with Olopatadine HCl nasal spray 0.4% and Olopatadine HCl nasal spray 0.6% compared with vehicle placebo.
Allergy and asthma proceedings, 2006Co-Authors: Frank C Hampel, Niran J Amar, Dale Mohar, Paul H Ratner, G. Michael Wall, Margaret Drake, Michael J. Brubaker, Julius Van Bavel, Carol J. Fairchild, Kimberly CrenshawAbstract:Seasonal allergic rhinitis (SAR) exerts a significant adverse impact on health-related quality of life (QoL) and productivity of those who suffer from it. Unfortunately, some therapies for SAR also have a negative impact. Therefore, it is important to scrutinize the influence of new SAR therapies on patients' QoL and ability to function. The purpose of this study was to evaluate the effect of a new nasal antihistamine, Olopatadine, on QoL in SAR patients. In a multicenter, randomized, double-blind SAR study comparing Olopatadine 0.6 and 0.4% to placebo nasal spray, patients completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at baseline and after 2 weeks of treatment. The RQLQ is a validated questionnaire that addresses overall QoL and 7 domains of impairment associated with rhinoconjunctivitis (activities, sleep, non--nose/eye allergy symptoms, practical problems, nasal symptoms, eye symptoms, and emotional impairment). The overall RQLQ mean changes from baseline with Olopatadine 0.6% (-1.1 +/- 1.4) and 0.4% (-1.1 +/- 1.3) nasal sprays were superior (p < 0.05) to placebo (-0.8 +/- 1.2). Olopatadine spray 0.6% was superior to placebo in six of the seven RQLQ domains and Olopatadine 0.4% was superior to placebo in five RQLQ domains (p < 0.05). The correlation between the Olopatadine 0.6% mean total symptom scores and mean RQLQ score was r = 0.66 (p < 0.0001), indicating that the enhancement in QoL derived from Olopatadine therapy was significantly associated with symptom reduction. Olopatadine nasal spray is an effective antiallergy medication that significantly improves the QoL of patients suffering from SAR.
T. Tamura - One of the best experts on this subject based on the ideXlab platform.
-
Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice.
The British journal of dermatology, 2007Co-Authors: T. Amano, T. Takeda, H. Yano, T. TamuraAbstract:Summary Background The skin barrier function in patients with atopic dermatitis is disrupted and prolonged topical steroid therapy produces epidermal barrier disturbance. Olopatadine hydrochloride (Olopatadine; Allelock®; Kyowa Hakko Kogyo Co., Ltd, Shizuoka, Japan) is an antiallergic drug with histamine H1 receptor antagonistic action. This drug alleviates skin inflammation and decreases the number of scratching episodes in a murine model of chronic contact dermatitis. Objectives To investigate the effects of Olopatadine and a steroid on the recovery of skin barrier function after barrier disruption in mice. Methods The skin barrier of the ears of mice was disrupted by tape stripping. The recovery of skin barrier function was monitored by measurement of transepidermal water loss (TEWL) after barrier disruption. Epidermal hyperplasia was induced by repeated tape stripping for 7 days. Olopatadine was administered orally once daily from 3 days before the first barrier disruption. Betamethasone 17-valerate (betamethasone) was applied topically once daily from 3 days before barrier disruption. Results Tape stripping led to a significant increase in TEWL. TEWL decreased with time after tape stripping and the skin barrier function recovered by over 60% within 9 h after tape stripping. The recovery of skin barrier in Olopatadine-treated mice was significantly accelerated, compared with that in vehicle-treated mice. In contrast, the skin barrier recovery in mice treated with topical betamethasone was significantly delayed, compared with that in vehicle-treated mice. Combined treatment with Olopatadine and betamethasone ameliorated the delay in barrier recovery induced by topical treatment with betamethasone. In addition, Olopatadine significantly prevented the increase in epidermal thickness induced by prolonged barrier disruption. Conclusions These results suggest that systemic administration of Olopatadine accelerates the recovery of skin barrier function and ameliorates the adverse effects of topical steroids on skin barrier recovery.
-
Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005Co-Authors: T. Tamura, M. Matsubara, K. Hasegawa, K. Ohmori, A. KarasawaAbstract:Background Olopatadine hydrochloride (Olopatadine; Allelock) is one of the second-generation antihistamines that are treated for allergic disorders such as rhinitis, urticaria and eczema dermatitis. Olopatadine has recently been shown to have inhibitory effects on the chronic contact hypersensitivity induced by repeated application of oxazolone in mice. Although topical steroids have widely been prescribed for atopic dermatitis, a relapse often occurs within several days after discontinuation of their prolonged use. Objectives We investigated the possible efficacy of Olopatadine against the relapse after discontinuation of prolonged use of topical prednisolone in the Balb/c mice with oxazolone-induced chronic contact hypersensitivity. Methods Mice with the chronic contact hypersensitivity induced by repeated application of oxazolone were treated with Olopatadine as a sequential therapeutic agent. The effects of Olopatadine were quantified by measurements of ear-swelling, and levels of cytokines and histamine in the lesioned ear. Results Topical prednisolone (0.05 mg/ear/day) significantly inhibited the increases in ear swelling and production of IL-1beta, IL-4, IL-18, granulocyte-macrophage colony-stimulating factor (GM-CSF) and histamine. However, after discontinuation of the treatment with topical prednisolone, the inflammation relapsed and the IL-4 level exceeded the control one. The sequential treatment with Olopatadine (10 mg/kg/day) after discontinuation of the treatment with topical prednisolone alone, or topical prednisolone with Olopatadine, significantly inhibited the increases in ear swelling and levels of IL-1beta, IL-4, IL-18, GM-CSF, nerve growth factor and histamine. Conclusions These results indicate that Olopatadine is an antihistamine agent having inhibitory activities against the rebound phenomenon following the discontinuation of topical steroid therapy. Olopatadine is thus expected to be a sequential therapeutic agent after discontinuation of the chronic treatment with a topical steroid.
Kimberly Crenshaw - One of the best experts on this subject based on the ideXlab platform.
-
Improved quality of life among seasonal allergic rhinitis patients treated with Olopatadine HCl nasal spray 0.4% and Olopatadine HCl nasal spray 0.6% compared with vehicle placebo.
Allergy and asthma proceedings, 2006Co-Authors: Frank C Hampel, Niran J Amar, Dale Mohar, Paul H Ratner, G. Michael Wall, Margaret Drake, Michael J. Brubaker, Julius Van Bavel, Carol J. Fairchild, Kimberly CrenshawAbstract:Seasonal allergic rhinitis (SAR) exerts a significant adverse impact on health-related quality of life (QoL) and productivity of those who suffer from it. Unfortunately, some therapies for SAR also have a negative impact. Therefore, it is important to scrutinize the influence of new SAR therapies on patients' QoL and ability to function. The purpose of this study was to evaluate the effect of a new nasal antihistamine, Olopatadine, on QoL in SAR patients. In a multicenter, randomized, double-blind SAR study comparing Olopatadine 0.6 and 0.4% to placebo nasal spray, patients completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at baseline and after 2 weeks of treatment. The RQLQ is a validated questionnaire that addresses overall QoL and 7 domains of impairment associated with rhinoconjunctivitis (activities, sleep, non--nose/eye allergy symptoms, practical problems, nasal symptoms, eye symptoms, and emotional impairment). The overall RQLQ mean changes from baseline with Olopatadine 0.6% (-1.1 +/- 1.4) and 0.4% (-1.1 +/- 1.3) nasal sprays were superior (p < 0.05) to placebo (-0.8 +/- 1.2). Olopatadine spray 0.6% was superior to placebo in six of the seven RQLQ domains and Olopatadine 0.4% was superior to placebo in five RQLQ domains (p < 0.05). The correlation between the Olopatadine 0.6% mean total symptom scores and mean RQLQ score was r = 0.66 (p < 0.0001), indicating that the enhancement in QoL derived from Olopatadine therapy was significantly associated with symptom reduction. Olopatadine nasal spray is an effective antiallergy medication that significantly improves the QoL of patients suffering from SAR.
-
Improved quality of life (QoL) among seasonal allergic rhinitis (SAR) patients treated with Olopatadine HCl nasal spray, 0.4% and Olopatadine HCl nasal spray, 0.6% compared to vehicle
The Journal of Allergy and Clinical Immunology, 2004Co-Authors: Frank C Hampel, Niran J Amar, M. Brubaker, J.h. Van Bavel, Dale Mohar, G.m. Wall, K Venkataraman, Paul H Ratner, M. Drake, Kimberly CrenshawAbstract:Abstract Rationale Since SAR causes a considerable impact on QoL, the Rhinoconjunctivitis Quality of Life (RQLQ) Questionnaire was used to assess the QoL impact of Olopatadine HCl nasal spray compared to the vehicle. Methods The 28-item RQLQ, consisting of 7 domains (activities, sleep, non-hayfever symptoms, practical problems, nasal symptoms, eye symptoms, and emotional), was used to collect QoL data during a multicenter, randomized, double-masked SAR (mountain cedar) trial comparing Olopatadine HCl nasal spray, 0.6% and 0.4% against the Olopatadine vehicle. Patients, recruited with at least a 2-yr history of non-recalcitrant SAR, filled out the questionnaire at baseline (randomization visit), and again after 2 weeks at the exit (end of treatment) visit. Results Olopatadine 0.6% (−1.1 + −1.4) and 0.4% (−1.1 + −1.3) nasal sprays were superior (p Conclusions Both Olopatadine HCl nasal sprays are superior to vehicle in improving overall QoL. While patients receiving Olopatadine HCl nasal spray, 0.6% had significantly demonstrable improvement in all areas of their life except non-hayfever symptoms, patients receiving Olopatadine 0.4% nasal spray had significant improvement in 5 out of the 7 total QoL areas.
